Catalog Products » IL-18BP hFc Chimera, Human
Manual
Manual
COAs

IL-18BP hFc Chimera, Human

Cytokines were the first modern immunotherapies to produce durable responses in patients with advanced cancer,components of the interleukin-18 (IL-18) pathway are upregulated on tumour-infiltrating lymphocytes, suggesting that IL-18 therapy could enhance anti-tumour immunity. IL-18BP, a high-affinity IL-18 decoy receptor, is frequently upregulated in diverse human and mouse tumours and limits the anti-tumour activity of IL-18 in mice.
$170.00
Z05453-100

Ask us a question
Product Introduction
Species Human
Protein Construction
IL-18BP (Thr31-Gly194)
Accession # O95998-2		 hFc
N-term C-term
Purity > 95% as determined by Bis-Tris PAGE
Endotoxin Level Less than 1EU per μg by the LAL method.
Biological Activity Measured by its binding ability in a functional ELISA. Test result was comparable to standard batch.
Expression System HEK293
Theoretical Molecular Weight 44.4 kDa
Apparent Molecular Weight Due to glycosylation, the protein migrates to 60-80 kDa based on Bis-Tris PAGE result.
Formulation Lyophilized from 0.22μm filtered solution in PBS (pH 7.4).
Reconstitution Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water.
Storage & Stability Upon receiving, the product remains stable for 6 months at -20℃ or below. Upon reconstitution, the product should be stable for 3 months at -80℃. Avoid repeated freeze-thaw cycles.
Back

IL-18BP HFc Chimera, Human

Immobilized Human IL-18, hFc Tag at 5 μg/ml (100 μl/well) on the plate. Dose response curve for IL-18BP hFc Chimera, Human, hFc Tag with the EC50 of 16.9 ng/ml determined by ELISA. »

IL-18BP HFc Chimera, Human

IL-18BP hFc Chimera, Human on Bis-Tris PAGE under reduced condition. The purity is greater than 95%. »

IL-18BP HFc Chimera, Human

IL-18BP hFc Chimera, Human, hFc Tag captured on Protein A chip, can bind Human IL-18 with an affinity constant of 0.04nM as determined in a SPR assay (Biacore T200). »

IL-18BP HFc Chimera, Human

The purity of IL-18BP hFc Chimera, Human is greater than 90% as determined by SEC-HPLC. »

<
>

Background
Target Background Cytokines were the first modern immunotherapies to produce durable responses in patients with advanced cancer,components of the interleukin-18 (IL-18) pathway are upregulated on tumour-infiltrating lymphocytes, suggesting that IL-18 therapy could enhance anti-tumour immunity. IL-18BP, a high-affinity IL-18 decoy receptor, is frequently upregulated in diverse human and mouse tumours and limits the anti-tumour activity of IL-18 in mice.
Synonyms IL-18BP; Igifbp
Back

For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.